Immix Biopharma, Inc. (IMMX): Total Liabilities
$11.04M
As of 2025-12-31
$10.19M
As of 2026-06-30
+84.9%
3-year compound annual growth
+15.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.04M | +13.9% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $9.70M | +160.5% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $3.72M | +112.9% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $1.75M | +765.3% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $202.0K | -96.2% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $5.27M | n/a | 2022-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $11.04M | +13.9% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $7.16M | +52.5% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $401.34M | +14.5% |
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $56.08M | +46.7% |
| iBio, Inc. (IBIO) | 2026-06-30 | $13.40M | +61.3% |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $233.76M | +272.0% |
| Rezolute, Inc. (RZLT) | 2026-06-30 | $12.16M | -9.0% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $62.07M | -5.7% |
Compare IMMX, TENX, CELU, KPTI side by side · Screen every company in Pharmaceutical Preparations ↗